Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections

Tirdad T. Zangeneh, Gio Baracco, Jaffar A. Al-Tawfiq

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Streptococcus pneumoniae-related infections have a major global impact on healthcare, especially in the developing world, and are considered the number one vaccine-preventable cause of death in children. There are more than 90 pneumococcal serotypes and 46 serogroups. The first capsular polysaccharide pneumococcal vaccine was licensed in the USA in 1977 for individuals older than 2 years of age at high risk for pneumococcal disease. Two decades later, the first 7-valent pneumococcal polysaccharide-protein conjugate vaccine completed the required clinical trials and was introduced as part of the national immunization program of various countries. New-generation vaccines that include emerging serotypes, while maintaining protection against the 7-valent pneumococcal serotypes, have recently been approved. With the addition of these serotypes, the majority of potential pneumococcal serotypes causing invasive disease in most parts of the world could be covered.

Original languageEnglish
Pages (from-to)345-353
Number of pages9
JournalExpert Review of Vaccines
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Pneumococcal Infections
Conjugate Vaccines
Pneumococcal Vaccines
Epidemiology
Vaccines
Immunization Programs
Polysaccharides
Serogroup
Cause of Death
Clinical Trials
Delivery of Health Care
Proteins

Keywords

  • pneumococcal vaccine
  • respiratory infection
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections. / Zangeneh, Tirdad T.; Baracco, Gio; Al-Tawfiq, Jaffar A.

In: Expert Review of Vaccines, Vol. 10, No. 3, 01.03.2011, p. 345-353.

Research output: Contribution to journalArticle

@article{03526fb785ce49cc9060c99b1fc140aa,
title = "Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections",
abstract = "Streptococcus pneumoniae-related infections have a major global impact on healthcare, especially in the developing world, and are considered the number one vaccine-preventable cause of death in children. There are more than 90 pneumococcal serotypes and 46 serogroups. The first capsular polysaccharide pneumococcal vaccine was licensed in the USA in 1977 for individuals older than 2 years of age at high risk for pneumococcal disease. Two decades later, the first 7-valent pneumococcal polysaccharide-protein conjugate vaccine completed the required clinical trials and was introduced as part of the national immunization program of various countries. New-generation vaccines that include emerging serotypes, while maintaining protection against the 7-valent pneumococcal serotypes, have recently been approved. With the addition of these serotypes, the majority of potential pneumococcal serotypes causing invasive disease in most parts of the world could be covered.",
keywords = "pneumococcal vaccine, respiratory infection, vaccination",
author = "Zangeneh, {Tirdad T.} and Gio Baracco and Al-Tawfiq, {Jaffar A.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1586/erv.11.1",
language = "English",
volume = "10",
pages = "345--353",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections

AU - Zangeneh, Tirdad T.

AU - Baracco, Gio

AU - Al-Tawfiq, Jaffar A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Streptococcus pneumoniae-related infections have a major global impact on healthcare, especially in the developing world, and are considered the number one vaccine-preventable cause of death in children. There are more than 90 pneumococcal serotypes and 46 serogroups. The first capsular polysaccharide pneumococcal vaccine was licensed in the USA in 1977 for individuals older than 2 years of age at high risk for pneumococcal disease. Two decades later, the first 7-valent pneumococcal polysaccharide-protein conjugate vaccine completed the required clinical trials and was introduced as part of the national immunization program of various countries. New-generation vaccines that include emerging serotypes, while maintaining protection against the 7-valent pneumococcal serotypes, have recently been approved. With the addition of these serotypes, the majority of potential pneumococcal serotypes causing invasive disease in most parts of the world could be covered.

AB - Streptococcus pneumoniae-related infections have a major global impact on healthcare, especially in the developing world, and are considered the number one vaccine-preventable cause of death in children. There are more than 90 pneumococcal serotypes and 46 serogroups. The first capsular polysaccharide pneumococcal vaccine was licensed in the USA in 1977 for individuals older than 2 years of age at high risk for pneumococcal disease. Two decades later, the first 7-valent pneumococcal polysaccharide-protein conjugate vaccine completed the required clinical trials and was introduced as part of the national immunization program of various countries. New-generation vaccines that include emerging serotypes, while maintaining protection against the 7-valent pneumococcal serotypes, have recently been approved. With the addition of these serotypes, the majority of potential pneumococcal serotypes causing invasive disease in most parts of the world could be covered.

KW - pneumococcal vaccine

KW - respiratory infection

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=79953239762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953239762&partnerID=8YFLogxK

U2 - 10.1586/erv.11.1

DO - 10.1586/erv.11.1

M3 - Article

C2 - 21434802

AN - SCOPUS:79953239762

VL - 10

SP - 345

EP - 353

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 3

ER -